US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Aktis Oncology, Inc. (AKTS): Radiopharmaceutical Sets Terms for IPO Seeking $840m Valuation

Aktis Oncology, Inc. (AKTS): Lilly Collaboration, Notable Backers Make for Intriguing IPO

Aktis Oncology, Inc. (AKTS): Radiopharmaceutical Bio IPO Delivers Breakout to Open 2026 Calendar

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Biotech is opening the 2026 IPO market, led by Aktis Oncology’s planned January 9 debut seeking up to $200 million.</li>
<li>Aktis is a clinical-stage oncology company developing next-generation targeted radiopharmaceuticals using proprietary miniprotein platforms to expand solid tumor treatment options.</li>
<li>Lead Nectin-4 program is in Phase 1b, supported by FDA IND clearance, a broad pipeline, and a high-value discovery collaboration with Eli Lilly.</li>
</ul>


Biotech is opening the 2026 IPO market, led by Aktis Oncology’s planned January 9 debut seeking up to $200 million.
Aktis is a clinical-stage oncology company developing next-generation targeted radiopharmaceuticals using proprietary miniprotein platforms to expand solid tumor treatment options.
Lead Nectin-4 program is in Phase 1b, supported by FDA IND clearance, a broad pipeline, and a high-value discovery collaboration with Eli Lilly.


アクティス・オンコロジー社（AKTS）：放射性医薬品会社のIPO目論見書を覗いてみよう